![As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study](https://cdn.cancerletter.com/media/2024/01/01044631/40-44-Rick-and-Erica-Kaitz-in-summer-2011.jpg)
![As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study](https://cdn.cancerletter.com/media/2024/01/01044631/40-44-Rick-and-Erica-Kaitz-in-summer-2011.jpg)
Cover Story
Free
Here is what we know: A surgical device used to perform about 100,000 hysterectomies and myomectomies every year in the U.S. has been shown to spread cells from undetected or missed uterine cancers—rapidly upstaging the disease.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages